| Literature DB >> 24330594 |
Simon Muhumuza1, Anne Katahoire, Fred Nuwaha, Annette Olsen.
Abstract
BACKGROUND: Realization of the public health benefits of mass drug administration (MDA) for the control of schistosomiasis depends on achieving and maintaining high annual treatment coverage. In Uganda, the uptake of preventive treatment for schistosomiasis among school-age children in 2011 was only 28%. Strategies are needed to increase uptake.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24330594 PMCID: PMC3866576 DOI: 10.1186/1471-2334-13-590
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Comparison of the included children at baseline and follow-up surveys
| 11.6 (1.8) | 11.5 (1.7) | 0.92 | |
| 555 (55.0%) | 543 (53.2%) | 0.55 | |
| 35.0% (354) | 32.6% (332) | 0.50 | |
| 156.7 | 133.1 | 0.38 |
Self-reported uptake of praziquantel at baseline and follow-up surveys
| 1 | 70 | 12 | 17.1 (2.08–48.4) | 75 | 44 | 58.7 (43.2–73.7) | 0.011 |
| 2 | 61 | 16 | 26.2 (7.27–52.3) | 70 | 39 | 55.7 (39.6–72.2) | 0.047 |
| 3 | 75 | 19 | 25.3 (9.14–51.2) | 70 | 44 | 62.9 (47.8–77.6) | 0.006 |
| 4 | 55 | 38 | 69.0 (51.3–82.4) | 71 | 28 | 39.4 (21.5–59.4) | 0.017 |
| 5 | 31 | 20 | 64.5 (40.7–84.6) | 73 | 30 | 41.4 (22.6–59.4) | 0.109 |
| 6 | 104 | 26 | 25.0 (11.5–47.8) | 100 | 45 | 45.0 (29.6–60.0) | 0.093 |
| 7 | 107 | 25 | 23.4 (9.35–45.1) | 100 | 53 | 53.0 (38.6–66.7) | 0.014 |
| 8 | 107 | 12 | 11.2 (0.21–38.4) | 92 | 56 | 60.9 (46.7–73.5) | 0.002 |
| 9 | 82 | 48 | 58.5 (43.2–72.4) | 71 | 42 | 59.2 (43.2–74.4) | 0.946 |
| 10 | 104 | 17 | 16.3 (3.70–43.4) | 101 | 55 | 54.5 (40.5–68.0) | 0.006 |
| 11 | 110 | 28 | 25.5 (10.6–44.9) | 98 | 13 | 13.3 (1.90–45.4) | 0.377 |
| 12 | 104 | 24 | 23.1 (9.77–46.7) | 99 | 50 | 50.5 (35.5–64.5) | 0.025 |
| Total | 1,010 | 285 | 28.2 (22.9–33.6) | 1,020 | 499 | 48.9 (44.4–53.4) | <0.001 |
Prevalence of infection at baseline and follow-up
| 1 | 70 | 24.3 (14.8–36.0) | 75 | 22.7 (13.7–33.7) | 0.82 |
| 2 | 61 | 19.7 (10.5–31.8) | 70 | 21.4 (12.5–32.9) | 0.81 |
| 3 | 75 | 36.0 (25.2–47.9) | 70 | 30.0 (19.6–32.9) | 0.44 |
| 4 | 55 | 94.5 (84.8–98.9) | 71 | 78.9 (67.5–87.6) | 0.01 |
| 5 | 31 | 96.8 (83.2–99.9) | 73 | 56.2 (44.0–67.8) | <0.001 |
| 6 | 104 | 55.8 (45.6–65.5) | 100 | 24.0 (16.0–33.5) | <0.001 |
| 7 | 107 | 35.5 (26.5–45.3) | 100 | 29.0 (20.3–38.9) | 0.39 |
| 8 | 107 | 30.0 (21.4–39.5) | 92 | 20.7 (12.9–30.4) | 0.13 |
| 9 | 82 | 34.2 (24.0–45.4) | 71 | 38.0 (26.8–50.3) | 0.63 |
| 10 | 104 | 19.2 (12.1–28.1) | 101 | 30.7 (21.8–40.7) | 0.06 |
| 11 | 110 | 21.0 (13.7–29.7) | 98 | 30.6 (21.6–40.7) | 0.11 |
| 12 | 104 | 16.3 (9.80–24.8) | 99 | 22.2 (14.4–31.7) | 0.29 |
| Total | 1,010 | 35.0 (25.4–37.9) | 1,020 | 32.6 (29.6–35.5) | 0.25 |
Intensity of infection at baseline and follow-up
| 1 | 70 | 42.7 (10.5–74.9) | 75 | 30.9 (-3.8–65.6)) | 0.62 |
| 2 | 61 | 22.6 (7.3–37.9) | 70 | 40.8 (0.8–80.8) | 0.42 |
| 3 | 75 | 35.7 (17.7–53.7) | 70 | 18.3 (9.1–27.5) | 0.09 |
| 4 | 55 | 1255.5 (798.3–1712) | 71 | 778.5 (435.4–1103.5) | 0.08 |
| 5 | 31 | 1419.1 (746.2–2092) | 73 | 541.5 (274.4–808.6) | 0.004 |
| 6 | 104 | 119.2 (61.6–176.8) | 100 | 87.8 (27.4–148.2) | 0.46 |
| 7 | 107 | 64.3 (27.5–101.1) | 100 | 53.0 (25.9–80.1) | 0.63 |
| 8 | 107 | 55.3 (22.7–87.9) | 92 | 22.0 (9.8–34.2) | 0.08 |
| 9 | 82 | 53.1 (7.5–98.7) | 71 | 111.6 (-16.8 –239.9) | 0.37 |
| 10 | 104 | 58.9 (-15.2–133.0) | 101 | 36.1 (19.7–52.5) | 0.56 |
| 11 | 110 | 11.7 (5.9–17.6) | 98 | 34.6 (18.4–50.8) | 0.01 |
| 12 | 104 | 10.1 (3.8–16.2) | 99 | 35.0 (11.9–58.0) | 0.03 |
| Total | 1010 | 156.7 (116.9–196.5) | 1,020 | 133.1 (99.0–167.2) | 0.38 |
GM (Geometric mean) intensity is among the positive cases only.